Are Independent Pharmacies The Missing Piece in Telehealth

Longevity Paid Content: Most telehealth companies solve exactly one problem: getting a prescription from a provider to a patient. What happens at the pharmacy end of that chain- whether the medication was filled correctly, whether the pharmacy is any good, whether the patient has any say in the matter at all – is usually treated as a detail rather than part of the product.  In this post, Mochi Health asks whether independent pharmacies are the missing piece in telehealth.

Mochi Health has built its business around the opposite assumption.

The company argues that independent pharmacies are not a logistical afterthought but the missing piece that determines whether telehealth works for the patient on the other end.  Where most platforms route every prescription through a single vendor with no visibility for the patient, Mochi has built a marketplace of independent pharmacies that patients can see, compare, and choose between, and the company argues that structural difference is what closes the gap between ordering a medication and being cared for.

The Piece Most Telehealth Companies Skip

The dominant model in direct-to-consumer telehealth treats the pharmacy as a black box. A patient answers a questionnaire, a provider prescribes, and the medication ships from whichever vendor the platform has a deal with. 

The patient never sees a name, a location, or a turnaround time, and has no way of knowing whether that pharmacy is well-run or simply the cheapest option the company could line up. If something goes wrong, the patient has no alternative to compare it against, because they were never shown one in the first place.

That arrangement also puts pressure on the pharmacies themselves. Independent pharmacies, Mochi has argued, are being squeezed as money is “extracted from the healthcare system” toward insurance companies, large drug manufacturers, and pharmacy-benefit managers, the intermediaries that sit between payers and the pharmacies filling prescriptions. 

The single-vendor pipeline model tends to reinforce that squeeze rather than relieve it, funneling volume to whichever pharmacy cuts the best deal rather than whichever pharmacy serves patients best.

Building a Marketplace Instead of a Pipeline

Mochi’s alternative is a three-sided marketplace connecting patients, providers, and independent pharmacies on one platform. 

The company has described its goal in direct terms: “a software-enabled marketplace that’s making pharmacies better at what they do, which results in better patient outcomes.” 

In practice, that means patients can see each pharmacy’s name, location, and turnaround time and choose accordingly, rather than being assigned one by default. The network behind that choice has grown quickly. Mochi has reported expanding from 10 pharmacy partners to 88 in a single quarter, with more than 100 partners in view, and says it verifies every partner and tests samples for purity and sterility before they’re added to the platform. 

Comparison only means something if every option meets a real bar, and that verification step is what’s meant to keep the marketplace from simply becoming a wider version of the same black box.

Why This Helps Pharmacies Too

The company is explicit that this model is meant to be provider- and pharmacy-friendly, rather than disruptive to the people filling prescriptions. 

“When pharmacies compete on service and quality, patients win,” Mochi has said of the network, and the company closes its own description of the model with a line that states its intent plainly: “better pharmacies mean better care for the patients who depend on them.”

The marketplace is designed to reward the pharmacies doing the work well, not to route around them.

For an independent pharmacy squeezed by PBMs and thin margins, being part of a marketplace that sends volume based on service and quality rather than the lowest bid is a meaningfully different proposition than being one interchangeable vendor in a single-source pipeline. 

Mochi bets that strengthening the pharmacies inside its network, rather than treating them as replaceable fulfillment, is what produces better outcomes for the patient at the end of the chain.

Why Patients Feel the Difference

For the patient, the payoff is continuity rather than a one-time transaction. Choosing a pharmacy, the same way a patient chooses a provider, means they can stick with one they trust as their care continues rather than being reassigned with each new prescription. 

That continuity is central to what Mochi has called the “discovery layer” of healthcare: a connective structure meant to help a patient find care they can keep, not just fill a script once and move on.

It also means a patient isn’t left guessing. Being able to compare a pharmacy’s location and turnaround time before committing turns what is usually an invisible part of telehealth into something a patient has actual visibility and choice over, closing a gap that most of the category has simply left open.

Leading a Different Model

Mochi is one of the few companies in this category that has built pharmacy partnership into the core of its platform rather than treating it as a vendor relationship handled behind the scenes. 

Growing from 10 partners to more than 80 is the kind of expansion that comes from a model other pharmacies want to be part of, not one they’re forced into. 

That is the marketplace working as designed. Pharmacies are chosen based on service and quality. Patients are given real choice, and a network that grows because it is worth joining.

As more in the category start to talk about pharmacy quality and access, Mochi’s position is that it isn’t following that conversation; it built the structure the conversation is now catching up to. Continuing to grow that network on the same terms- verification first, choice for the patient, real accountability for the pharmacy- is what it means to lead on this problem rather than simply acknowledge it exists.

MAIN IMAGE CREDIT: Photo by Roberto Sorin on Unsplash